MAY 18, 2017 2:22 PM PDT

Treating A Rare Immunological Disease with Mepolizumab

WRITTEN BY: Kara Marker

There's a new standard treatment for a rare immunological disease: mepolizumab. No need for an approval process, though - the drug is already approved by the U.S. Food and Drug Administration (FDA) to treat another disease.

Micrograph showing high power view of Eosinophils. Credit: Department of Pathology, Calicut Medical College

The identification of a new treatment is promising news for people with the rare disease, called eosinophilic granulomatosis with polyangiitis (EGPA). Previously known as Churg-Strauss Syndrome, EGPA is characterized by excessive proliferation of eosinophils, a type of proinflammatory white blood cell involved in multiple immune processes, including allergic reactions. As the eosinophil population grows, cells start to collect in the blood vessel walls, meanwhile releasing toxic, inflammatory proteins that damage tissues around them.

An individual developing EGPA will first experience only severe asthma, but as time goes by, more blood flow is restricted, and more tissues are damaged, multi-organ damage will occur. Prior to mepolizumab, the only standard treatments for EGPA were oral steroids, taken regularly, and occasionally immunosuppressants. However, both options are accompanied by adverse side effects, relapses are common, and treatment doesn’t always work for some EGPA patients.

Mepolizumab was originally approved by the FDA to treat serious cases of eosinophilic asthma; the drug is a humanized monoclonal antibody of immunoglobulin G, and it targets an immune chemical called interleukin-5 to treat asthma.

The new phase 3 Clinical Trial, from the National Institute of Allergy and Infectious Diseases, examined the improvements made in patients when mepolizumab is added to steroid treatments for EGPA. Researchers conducted a double-blind experiment of 136 EGPA participants, where half of the study’s participants received mepolizumab and half received a placebo. All of the study’s participants either did not respond at all to steroids or relapsed after taking oral steroids.

Regardless of whether or not they also took immunosuppressants, nearly one-third of people receiving mepolizumab remained in remission for at least 24 weeks, but only three percent of the placebo participants remained in remission for that long.

The next step for getting mepolizumab into the hands of people struggling with EGPA: What biological markers can distinguish between people who would benefit from mepolizumab and those who would not?

The present study was published in the New England Journal of Medicine.

Sources: NIH/National Institute of Allergy and Infectious Diseases, Expert Review of Clinical Immunology, Cincinnati Center for Eosinophilic Disorders

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 08, 2020
Drug Discovery & Development
APR 08, 2020
Does Tuberculosis Vaccine Really Defend from COVID-19?
The spread of COVID-19 has panned out very differently in different countries. While in some such as the US, the UK and ...
APR 13, 2020
Drug Discovery & Development
APR 13, 2020
Are COVID-19 Antibody Tests a Back-to-Work Pass?
Although treatments and vaccines against COVID-19 may still be months away, antibody tests are becoming more widespread. ...
APR 17, 2020
Neuroscience
APR 17, 2020
Anti Vaxxers More Paranoid than Average Person
Researchers from Texas Tech University have found that anti-vaxxers (those who deny the efficacy of vaccines) are more p ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Gilead's Remdesivir Trial Sees Rapid Recoveries from COVID-19
Early results from a Chicago hospital treating patients with Gilead Sciences’ antiviral drug remdesivir for severe ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
COVID-19 Vaccine On Track for Late 2020
Moderna, a biotechnology company based in Massachusetts, has released information on its vaccine against COVID-19 from i ...
Loading Comments...